There’s no shortage of ambition at GlaxoSmithKline, whose chief immunology officer and senior vice president of their R&D pipeline Paul-Peter Tak we spoke to for this month’s executive interview.
Having joined the company five years ago from an academic medical centre in Amsterdam, he says he was driven to move to the industry because he wanted to have a bigger impact on patients’ lives.
“The dream is, if you can develop a medicine that can cure rheumatoid arthritis or can prevent type 1 diabetes, then you have done something really good during your career,“ he says.
Doing more good – and joining the pharmaceutical industry to do so – is a common theme for those in research, but bold efforts can be made in all areas of the industry, as is discussed in this month’s cover feature Turning healthcare on its head.
It takes aim at how to turn pharma’s oft-mentioned desire to be more ‘patient-centric’ into reality.
It’s a challenge that unites providers, healthcare professionals, payers and policymakers, as recognition at all levels grows of the importance of multi-stakeholder collaboration in developing effective health interventions.
As one contributor to the feature notes: “The best examples of patient-centric work are bold, brave and creative.”
• Read the October 2016 issue of PME
The issue in numbers
It’s estimated that more than 80% of cancer trials fail to reach their recruitment goals
Rare cancers – of which around 200 have been identified so far – account for 22% of all cancer cases in the European Union
Millennials are estimated to comprise 75% of the global workforce by 2025…
…but probably not those on pharma boards – where 42% of members are currently aged 65 and over